Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.54+0.01 (+2.72%)
Close on Nov 17, 2026Market cap $2.26MP/E –Yield –
Valion Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Valion Bio's revenue for the twelve months ending Sep 30, 2025 was $482.00K, down 49.6% year over year. For fiscal 2024 it was $780.00K, down 33.7% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $780.00K | -33.7% |
| FY2023 | Dec 31, 2023 | $1.18M | -36.1% |
| FY2022 | Dec 31, 2022 | $1.84M | +46.4% |
| FY2021 | Dec 31, 2021 | $1.26M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $146.00K | +15.9% |
| Q2 FY2025 | Jun 30, 2025 | $86.00K | -38.6% |
| Q1 FY2025 | Mar 31, 2025 | $70.00K | -79.0% |
| Q4 FY2024 | Dec 31, 2024 | $180.00K | -49.6% |
| Q3 FY2024 | Sep 30, 2024 | $126.00K | -55.3% |
| Q2 FY2024 | Jun 30, 2024 | $140.00K | -13.0% |
| Q1 FY2024 | Mar 31, 2024 | $334.00K | -11.2% |
| Q4 FY2023 | Dec 31, 2023 | $357.00K | -12.5% |
| Q3 FY2023 | Sep 30, 2023 | $282.00K | -40.9% |
| Q2 FY2023 | Jun 30, 2023 | $161.00K | -69.5% |
| Q1 FY2023 | Mar 31, 2023 | $376.00K | -12.1% |
| Q4 FY2022 | Dec 31, 2022 | $408.00K | +4.9% |
| Q3 FY2022 | Sep 30, 2022 | $477.00K | +72.2% |
| Q2 FY2022 | Jun 30, 2022 | $528.00K | +97.0% |
| Q1 FY2022 | Mar 31, 2022 | $428.00K | +32.5% |
| Q4 FY2021 | Dec 31, 2021 | $389.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $277.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $268.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $323.00K | – |
See a number that looks wrong?